Levo-Dromoran
(Levorphanol)PreclinicalSmall molecule
Levo-Dromoran is one of 6 small molecule programs targeting Tolerance. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
5
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
9 competitors in Tolerance
#DrugCompanyPhaseTrials
1Avigan
AAppili Therapeutics Inc.
Phase 2
Experimental
BiogenPreclinical
Levo-Dromoran
VValeant Pharmaceuticals
Preclinical
Siplizumab
UUniversity of Alabama at Birmingham
Preclinical
Oxytocin Treatment
UUniversity of Electronic Science and Technology of China
Preclinical
Tazorac
FFougera Pharmaceuticals Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Dec 19, 1991
LEVO-DROMORAN
NDA NDA008719
Dec 19, 1991
LEVO-DROMORAN
NDA NDA008720
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Levorphanol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- VValeant Pharmaceuticals